west china medical publishers
Keyword
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Keyword "Valvular heart disease" 22 results
  • A postoperative in-hospital mortality risk model for elderly patients undergoing cardiac valvular surgery based on LASSO-logistic regression

    Objective To evaluate the risk factors for postoperative in-hospital mortality in elderly patients receiving cardiac valvular surgery, and develop a new prediction models using the least absolute shrinkage and selection operator (LASSO)-logistic regression. Methods The patients≥65 years who underwent cardiac valvular surgery from 2016 to 2018 were collected from the Chinese Cardiac Surgery Registry (CCSR). The patients who received the surgery from January 2016 to June 2018 were allocated to a training set, and the patients who received the surgery from July to December 2018 were allocated to a testing set. The risk factors for postoperative mortality were analyzed and a LASSO-logistic regression prediction model was developed and compared with the EuroSCOREⅡ. Results A total of 7 163 patients were collected in this study, including 3 939 males and 3 224 females, with a mean age of 69.8±4.5 years. There were 5 774 patients in the training set and 1389 patients in the testing set. Overall, the in-hospital mortality was 4.0% (290/7163). The final LASSO-logistic regression model included 7 risk factors: age, preoperative left ventricular ejection fraction, combined coronary artery bypass grafting, creatinine clearance rate, cardiopulmonary bypass time, New York Heart Association cardiac classification. LASSO-logistic regression had a satisfying discrimination and calibration in both training [area under the curve (AUC)=0.785, 0.627] and testing cohorts (AUC=0.739, 0.642), which was superior to EuroSCOREⅡ. Conclusion The mortality rate for elderly patients undergoing cardiac valvular surgery is relatively high. LASSO-logistic regression model can predict the risk of in-hospital mortality in elderly patients receiving cardiac valvular surgery.

    Release date: Export PDF Favorites Scan
  • Clinical Observation of Left Ventricular Remodeling after Valve Replacement for Valvular Heart Disease with Giant Left Ventricle

    Objective To evaluate the left ventricular remodeling after valve replacement for valvular heart disease with giant left ventricle. Methods The clinical material of 92 patients with valvular heart disease and giant left ventricle after valve replacement was retrospectively reviewed. The results of ultrosonic cardial gram(UCG) and the changes of cardiac function before and after operation were compared. Results There was no operative death. The value of left ventricular end-diastolic dimension (LVEDD), left ventricular end-systolic dimension (LVESD), left atrial dimension (LAD), left ventricular ejection fraction (LVEF), left ventricular fractional shortening (LVFS), stroke volume (SV) and cardiothoracic ratio in 2 weeks and 2 months after operation were more decreased than those before operation(P〈0. 05). The value of LVEDD and LAD in 2 months after operation were much more decreased than those in 2 weeks after operation (P〈0. 05). The cardiac function in early stage after operation was more decreased than that before operation,but the cases of cardiac functional class Ⅱ (38 cases, 41.3% ) in 2 months after operation was significantly more than those before operation (5 cases, 5.4 % ). Conclusions The early effect of left ventricular remodeling is significant for valvular heart disease with giant left ventricle after valve replacement. The diameter of left ventricle and left atrial are significantly decreased after operation. The protection for cardiac function should be carefully taken in order to prevent the occurrence of complication after operation.

    Release date:2016-08-30 06:22 Export PDF Favorites Scan
  • Global and China-US epidemiology and treatment status of valvular heart disease

    Objective To systematically analyze the disease burden, long-term trends, and age-sex distribution of major valvular heart disease (VHD) subtypes—rheumatic heart disease (RHD), non-rheumatic valvular disease (NRVD), and non-rheumatic calcific aortic valve disease (CAVD)—in global, Chinese, and US populations from 1990 to 2021, providing evidence for public health strategies and clinical resource allocation. Methods Based on publicly available data from the Global Burden of Disease (GBD) Study 2021, we extracted incidence, mortality, and disability-adjusted life years (DALYs) for VHD from 1990 to 2021. Age-standardized rates (ASRs) were calculated using the GBD 2021 global standard population, and the estimated annual percentage change (EAPC) with its 95% uncertainty interval (UI) was computed for the period. Data from the US Healthcare Cost and Utilization Project (HCUP), the European Society of Cardiology (ESC)/Eurostat surveys, and Chinese national registries were used for trend triangulation and contextual background. Results From 1990 to 2021, the ASR and disease burden of RHD significantly decreased globally and in China (EAPC for DALYs in China: -2.15%, 95% UI: -2.28% to -2.02%). In contrast, the burden of NRVD and CAVD has been steadily increasing in aging populations like those in China and the US, with a higher burden observed in older adults and males. In 2021, the incidence of NRVD and CAVD peaked in individuals aged ≥65 years, with rates being significantly higher in men than in women. RHD burden was concentrated in low Socio-demographic Index (SDI) regions, whereas NRVD/CAVD burden was strongly associated with high-SDI regions. ConclusionThe global VHD epidemiological landscape is transitioning from an RHD-dominant to an NRVD/CAVD-dominant pattern. China faces a dual challenge of a residual RHD burden and a rapidly growing burden of degenerative valvular diseases. Developing tailored screening, prevention, and treatment strategies for different disease subtypes and populations is crucial.

    Release date: Export PDF Favorites Scan
  • Preliminary effectiveness of the whole-life cycle management model for valvular heart disease at West China Hospital: A retrospective cohort study

    Objective To propose a whole-life cycle management model for valvular heart disease (VHD), systematically elucidate its underlying logic and implementation pathways, and concurrently review and analyze its preliminary application outcomes. Methods Since 2020, West China Hospital of Sichuan University has established a management system encompassing "assessment-decision-intervention-follow-up", including: (1) a risk-stratified, tiered management pathway; (2) six core functions ("promotion, screening, prevention, diagnosis, treatment, and rehabilitation") coordinated by disease-specific managers; (3) an intelligent decision support information platform; and (4) a collaborative network of multidisciplinary teams and regional academic alliances. To evaluate the effectiveness of this management model, we retrospectively included three cohorts: (1) the population screened by echocardiography from 2020 to 2024, analyzing the detection rate of aortic valve disease and risk stratification; (2) patients enrolled in the whole-life cycle management from April 2021 to December 2024, assessing follow-up outcomes, hospital satisfaction, and changes in quality of life; (3) patients who underwent transcatheter aortic valve replacement (TAVR) from January 2022 to January 2024, evaluating the one-year all-cause mortality rate, perioperative complications, and improvements in New York Heart Association (NYHA) classification. Results Between 2020 and 2024, a total of 583 874 individuals underwent echocardiographic screening. A total of 48 089 patients with aortic valve disease were identified, including 3 401 (7.1%) high-risk patients, 18 657 (38.8%) moderate-risk patients, and 26 031 (54.1%) low-risk patients. Among them, 2 417 patients were enrolled in whole-life cycle management. Patient satisfaction scores showed a yearly increase, rising from 73.89 points before 2020 to 93.74 points in 2024. The 1-year mortality rate in the TAVR cohort decreased to 5.3%, significantly lower than the 8.2% observed under early standard management between 2014 and 2019 (P<0.01). Conclusion Through process optimization and resource integration, the VHD whole-life cycle management model has demonstrated significant effectiveness in standardizing diagnostic and follow-up procedures, enhancing patient satisfaction and quality of life, and reducing mortality. These outcomes highlight its practical value for broader implementation in China.

    Release date:2025-06-24 11:15 Export PDF Favorites Scan
  • Update on transcatheter aortic valve replacement (TAVR) in the latest 2017 European Society of Cardiology (ESC)/European Association for Cardio-Thoracic Surgery (EACTS) guidelines for the management of valvular heart disease

    Since the 2012 European Society of Cardiology (ESC)/European Association of Cardio-Thoracic Surgery (EACTS) guidelines on the management of valvular heart disease, a large amount of new data have accumulated. The new evidence has led to an update of the ESC/EACTS guidelines for the management of valvular heart disease in order to have consensus among cardiologists and cardiac surgeons. This article aims to give an update and comprehensive overview on the position of transcatheter aortic valve replacement in the latest 2017 ESC/EACTS guidelines for the management of valvular heart disease.

    Release date:2018-02-26 05:32 Export PDF Favorites Scan
  • 2017 ACC/AHA Focused Update of the Guideline for the Management of Patients with Valvular Heart Disease: key messages and future insights

    There has been substantial progress in the field since the publication of the 2014 American College of Cardiology /American Heart Association Guideline for the Management of Valvular Heart Disease, thus mandating a timely update. Major modifications that were highlighted in the 2017 Focused Update include the treatment choice for aortic stenosis, management of mitral regurgitation, the selection of prosthetic valve type and antiplatelet/antithrombotic therapy for bioprostheses. The current review aims at providing a reasonable interpretation of the most important messages conveyed in the 2017 Focused Update and their implications for the future development of this area.

    Release date:2018-02-26 05:32 Export PDF Favorites Scan
  • Research progress on the quality of life in patients after cardiac valve replacement

    Valvular heart disease is one of the common diseases in cardiac surgery. Surgery is the main treatment for valvular heart disease. Cardiac valve replacement surgery corrects the disordered haemodynamics, but the quality life of patients may be affected by multiple factors, such as the disease itself, treatment measures, long-term postoperative anticoagulant and follow-up. This article will provide an overview of the quality of life (origin and definition, evaluation) and the quality of life of patients after cardiac valve replacement (the purpose and significance of quality of life assessment, the quality of life of patients after cardiac valve replacement at different times and different dimensions, influencing factors of the quality of life of patients after surgery), aiming to provide clinical evidence for patients to make decisions before surgery and for clinical medical staff to take intervention measures for patients after surgery.

    Release date:2020-08-25 10:08 Export PDF Favorites Scan
  • The surgical treatment strategy and perioperative management of patients with heart valve disease complicated with severe chronic heart failure

    ObjectiveTo summarize the individualized selection of surgical treatment strategies and the key points of perioperative management for patients with heart valve disease complicated with severe chronic heart failure.MethodsThe clinical characteristics of 5 male patients with valvular heart disease complicated with severe chronic heart failure (CHF) were analyzed retrospectively from June 2017 to October 2018 in Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, with an average age of 60.21 years.ResultsFive patients were given angiotensin receptor and neprilysin inhibitor (ARNI)-based anti-heart failure treatment after admission. The operation mode of these patients was decided to be valve replacement under cardiopulmonary bypass after individualized evaluation of patients’ improving symptoms. Three patients were treated with intra-aortic balloon pump (IABP) and continuous renal replacement therapy (CRRT) early after operation to assist patients in improving cardiac function. Five patients recovered oral anti-heart failure after awakening. All patients were discharged smoothly 2 weeks after operation.ConclusionIndividualized evaluation is needed for the choice of operation timing and mode, standardized preoperative treatment for heart failure, shortening the aortic blocking time during cardiopulmonary bypass, and early application of left ventricular adjuvant drugs or instruments are all important measures to help patients recover smoothly.

    Release date:2019-09-18 03:45 Export PDF Favorites Scan
  • Risk Factors of In-hospital Death after Heart Valve Replacement in Xinjiang

    ObjectiveTo investigate risk factors of in-hospital death of patient after heart valve replacement (HVR) in Xinjiang. MethodsWe retrospectively analyzed clinical data of 214 patients undergoing HVR in the First Teaching Hospital of Xinjiang Medical university from January 2011 to Month 2014. There were 96 male and 118 female patients with their age of 49.91±13.27 years. According to their postoperative prognosis, all the patients were divided into a death group (21 patients) and a survival group (193 patients). Risk factors of perioperative death were analyzed. ResultsIn-hospital mortality was 9.81% (21/214). There was statistical difference in preoperative prothrombin time (PT), incidences of left ventricular ejection fraction (LVEF)≤50%, NYHA classⅣ, pulmonary arterial pressure (PAP) > 60 mm Hg, cardiopulmonary bypass time≥2 hours, concomitant coronary artery disease and renal failure between the 2 groups (P < 0.05). Logistic regression analysis showed that shortened preoperative PT, PAP > 60 mm Hg, NYHA classⅣand LVEF≤50% were independently risk factors of in-hospital death after HVR (P < 0.05). ConclusionsIndependent risk factors of in-hospital death of patients after HVR in Xinjiang include shortened preoperative PT, PAP > 60 mm Hg, NYHA classⅣand LVEF≤50%. Heightened caution is needed for patients with above risk factors to receive HVR after correction of those risk factors.

    Release date:2016-10-02 04:56 Export PDF Favorites Scan
  • Myocardial Protection by Different Myocardial Protective Strategies in Double Valve Replacement

    Abstract: Objective To evaluate myocardial protection effect of different myocardial protective strategies for patients undergoing double valve replacement (DVR) . Methods From Jun. 2005 to Dec. 2005, 32 patients with predominant aortic valve stenosis undergoing DVR in Xinqiao Hospital were included in this study. These patients were randomly divided into four groups with 8 patients in each group: (1) antegrade perfusion group:Cold-blood cardioplegia was delivered antegradely through aortic root, and mitral valve replacement (MVR)was performed. Then cold-blood cardioplegia was delivered antegradely through left and right coronary ostia, and aortic valve replacement (AVR) was performed; (2)retrograde perfusion group:Cold-blood cardioplegia was delivered retrogradely and intermittently through coronary sinus, and DVR was performed; (3)antegrade+retrograde perfusion group:The route of cold-blood cardioplegic infusion was antegrade during MVR procedure first and then retrograde during AVR procedure;and (4)beating heart group:Oxygenated blood from cardiopulmonary bypass machine was delivered retrogradely and continuously through coronary sinus, and DVR was performed with beating heart. Early clinical outcomes were observed. Serum cardiac troponin I (cTnI) was measured by enzyme-linked immunosorbent assay(ELISA). Serum creatine kinase-MB (CK-MB) and myocardial lactic acid release rate were measured by Hitachi7150 Automatic Chemistry Analyzer. Myocardial mitochondria malondialdehyde (MDA) level was measured through thiobarbituric acid reagent species analysis. Results All the 32 patients survived their surgery and were discharged successfully. Myocardial lactic acid release rate at 80 min after aortic cross-clamping, serum cTnI and CK-MB on the first postoperative day, myocardial mitochondria MDA levels of beating heart group were 13.59%±6.27%,(1.17±0.25) ng/ml, (56.43±16.50) U/L and(2.18±1.23) nmol/(ng.prot)respectively, all significantly lower than those of retrograde perfusion group [(33.49%±8.29%, (1.82±0.58 )ng/ml, (78.31±21.27) U/L (5.07±2.35) nmol/(ng.prot),P<0.05] and antegrade+retrograde perfusion group[20.87%±7.22%, (1.49±0.23) ng/ml,(66.67±19.13) U/L,(4.34±1.73) nmol/(ng.prot),P<0.05], but not statistically different from those of antegrade perfusion group [18.83%±5.97%, (1.41±0.32) ng/ml, (63.21±37.52) U/L, (3.46±1.62) nmol/ (ng.prot),P>0.05]. Conclusion All the four myocardial protective strategies are effective myocardial protection methods for DVR patients. Continuous retrograde perfusion with beating heart and intermittent antegrade perfusion can provide better myocardial protection, and therefore are preferred for DVR patients. The combination of antegrade and retrograde perfusion is easy to administer and does not negatively influence surgical procedures. Retrograde perfusion is also effective as it takes only a short time.

    Release date:2016-08-30 05:50 Export PDF Favorites Scan
3 pages Previous 1 2 3 Next

Format

Content